|Bid||32.15 x 1200|
|Ask||32.49 x 1100|
|Day's Range||31.08 - 32.44|
|52 Week Range||3.74 - 53.69|
|Beta (5Y Monthly)||1.12|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||47.25|
MENLO PARK, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted restricted stock units (“RSUs”) covering 29,500 shares of Pacific Biosciences common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PacBio's (PACB) latest acquisition is expected to deliver the most advanced blend of sequencing solutions to transform the genomics landscape.